Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

NCT01006616 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

616

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Navarixin
DRUG: Placebo
DRUG: Rescue medication

Sponsor

Merck Sharp & Dohme LLC